SIOX
Sio Gene Therapies Inc. [SIOX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SIOX Stock Summary
In the News
SIOX Financial details
Company Rating
-
Market Cap
35.36M
Income
-28.17M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
12 Feb 2024
P/E
-4.47
Forward P/E
-
PEG
1.14
P/S
-
P/B
0.64
P/C
-
P/FCF
-2.79
Quick Ratio
21.6
Current Ratio
21.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.38
EPS next Y
-
EPS next Q
-
EPS this Y
58.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
13.24%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-14%
ROE
-14%
ROC
-0.17%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.25-0.5
52W High
-
52W Low
-
RSI
-
Rel Volume
0.12
Avg Volume
62.41K
Volume
7.59K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.085
-
-
Volatility
0.03%, 0.03%
Prev Close
15.18%
Price
0.478
Change
-
Company Profile
- Volume Average 62.41K
- Market Capitalization 35.36M
- Employee 12
- CEO Mr. David W. Nassif J.D.
- Headquarters New York,NY,US
- IPO Date 2015-06-11
-
Website
https://www.siogtx.com 
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
